BACKGROUND: Acute bacterial skin and skin-structure @entity281 (ABSSSIs) are common causes of hospital admissions. These @entity281 are often caused by @entity3256 -resistant @entity794 ; therefore, @entity2176 remains a commonly used therapy. The purpose of this study was to compare hospital length of stay (LOS) in @entity1 treated with @entity2176 monotherapy vs combination therapy with @entity3402 for ABSSSIs. METHODS: This was a retrospective analysis of 269 @entity1 admitted with ABSSSIs to a 941-bed hospital in northern Alabama. @entity1 who received either @entity2176 monotherapy or @entity2176 in combination with @entity3402 were included. The primary outcome was hospital LOS; secondary outcomes included 90-day readmission rate and the impact of the following on the primary outcome: organisms cultured, presence of abscess, incision and debridement (I_D), failure of a trial of outpatient antibiotics, and presence of @entity6 . RESULTS: Hospital LOS was similar between groups when evaluating all ABSSSIs (3.7    1.5 days vs 4.0    2.0 days, P = .192, combination and monotherapy, respectively). In @entity1 with abscesses, combination therapy was significantly associated with decreased LOS by 18.2% compared with monotherapy (95% confidence interval [CI], 0.818 [.679 to .985]; P = .034). Among the entire population, significantly fewer @entity1 in the combination group were readmitted within 90 days (5.3% vs 15.3%; P = .006; odds ratio [OR], 3.2; 95% CI [1.35 to 7.66]). The 90-day readmission rates were significantly lower among @entity1 with abscesses as well (2.0% vs 24.3%; P = .0001; OR, 14.6; 95% CI [2.98 to 71.37]). CONCLUSIONS: Combination therapy with @entity2176 and @entity3402 was associated with decreased hospital LOS for @entity1 with an abscess. The 90-day hospital readmission rates for those with ABSSSIs may be reduced when combination therapy is utilized. A larger, prospective, multicentered study is needed to validate these findings.

@entity2176 Combined With XXXX for the Treatment of Acute Bacterial Skin and Skin-Structure Infections.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity3256 :: ('MESH:D008712', 'Chemical') :: ['methicillin'] @entity2176 :: ('MESH:D014640', 'Chemical') :: ['vancomycin'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes'] @entity794 :: ('1280', 'Species') :: ['Staphylococcus aureus'] @entity281 :: ('MESH:D007239', 'Disease') :: ['infections'] @entity3402 :: ('MESH:D002981', 'Chemical') :: ['clindamycin']
@entity3402 :: (MESH:D002981,Chemical) :: ['Clindamycin']
